复发性或第二原发性头颈部鳞状细胞癌的TP53遗传异质性。

IF 4.9 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology Pub Date : 2025-01-10 DOI:10.1016/j.radonc.2025.110714

Liyona Kampel, Sara Feldstein, Shlomo Tsuriel, Leonor Leider Trejo, Gilad Horowitz, Anton Warshavsky, Jobran Mansour, Dov Hershkovitz, Nidal Muhanna

{"title":"复发性或第二原发性头颈部鳞状细胞癌的TP53遗传异质性。","authors":"Liyona Kampel, Sara Feldstein, Shlomo Tsuriel, Leonor Leider Trejo, Gilad Horowitz, Anton Warshavsky, Jobran Mansour, Dov Hershkovitz, Nidal Muhanna","doi":"10.1016/j.radonc.2025.110714","DOIUrl":null,"url":null,"abstract":"Head and neck squamous cell carcinomas (HNSCC) frequently recur, and patients often develop second primary tumors. Their distinction is clinically challenging. TP53 mutational heterogeneity may indicate novel molecular events rather than resistant clones' expansion or persistent disease. Surveillance and therapeutic strategies should be adjusted, especially in the case of a second primary arising in an already irradiated field.","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"110714"},"PeriodicalIF":4.9000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma.\",\"authors\":\"Liyona Kampel, Sara Feldstein, Shlomo Tsuriel, Leonor Leider Trejo, Gilad Horowitz, Anton Warshavsky, Jobran Mansour, Dov Hershkovitz, Nidal Muhanna\",\"doi\":\"10.1016/j.radonc.2025.110714\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Head and neck squamous cell carcinomas (HNSCC) frequently recur, and patients often develop second primary tumors. Their distinction is clinically challenging. TP53 mutational heterogeneity may indicate novel molecular events rather than resistant clones' expansion or persistent disease. Surveillance and therapeutic strategies should be adjusted, especially in the case of a second primary arising in an already irradiated field.\",\"PeriodicalId\":21041,\"journal\":{\"name\":\"Radiotherapy and Oncology\",\"volume\":\" \",\"pages\":\"110714\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-01-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiotherapy and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.radonc.2025.110714\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiotherapy and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.radonc.2025.110714","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

头颈部鳞状细胞癌（HNSCC）经常复发，患者经常发展为第二原发肿瘤。它们的区别在临床上具有挑战性。TP53突变异质性可能表明新的分子事件，而不是耐药克隆扩增或持续疾病。应调整监测和治疗策略，特别是在已经辐照的领域中出现第二原发病例的情况下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma.

Head and neck squamous cell carcinomas (HNSCC) frequently recur, and patients often develop second primary tumors. Their distinction is clinically challenging. TP53 mutational heterogeneity may indicate novel molecular events rather than resistant clones' expansion or persistent disease. Surveillance and therapeutic strategies should be adjusted, especially in the case of a second primary arising in an already irradiated field.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Radiotherapy and Oncology 医学-核医学

CiteScore

10.30

自引率

10.50%

发文量

2445

审稿时长

45 days

期刊介绍： Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, translational studies, epidemiological outcomes, imaging, dosimetry, and radiation therapy planning, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as data science in radiation oncology and physics aspects relevant to oncology.Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.